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hematopoietic stem cell maintenance 
is critical for acute myeloid leukemia
PM Korthuis, G Berger, B Bakker, M Geugien, J Jaques, G de Haan, 






As the transcriptional coactivator CITED2 (CBP/p300-interacting-transactivator-
with-an ED-rich-tail 2) can be overexpressed in acute myeloid leukemia (AML) cells, 
we analyzed the consequences of high CITED2 expression in normal and AML cells. 
CITED2 overexpression in normal CD34+ cells resulted in enhanced hematopoietic 
stem and progenitor cell (HSPC) output in vitro, as well as in better hematopoietic stem 
cell (HSC) engraftability in NSG mice. This was because of an enhanced quiescence 
and maintenance of CD34+CD38- HSCs, due in part to an increased expression of the 
cyclin-dependent kinase inhibitor CDKN1A. We demonstrated that PU.1 is a critical 
regulator of CITED2, as PU.1 repressed CITED2 expression in a DNA methyltransferase 
3A/B (DNMT3A/B)-dependent manner in normal CD34+ cells. CD34+ cells from a 
subset of AML patients displayed higher expression levels of CITED2 as compared 
with normal CD34+ HSPCs, and knockdown of CITED2 in AML CD34+ cells led to 
a loss of long-term expansion, both in vitro and in vivo. The higher CITED2 expression 
resulted from reduced PU.1 activity and/or dysfunction of mutated DNMT3A/B.  
Collectively, our data demonstrate that increased CITED2 expression results in better 
HSC maintenance. In concert with low PU.1 levels, this could result in a perturbed 
myeloid differentiation program that contributes to leukemia maintenance.
T he transcriptional coactivator C B P / p 3 0 0 - i n t e r a c t i n g -transactivator-with-an ED-
rich-tail 2 (CITED2) was originally 
discovered to bind the CH1 region of  
CBP/p300.(1) More recently, we showed 
that CITED2 is essential for adult HSC 
maintenance.(2) CITED2 deletion in 
adult HSCs led to rapid animal lethality, 
resulting from hematopoietic stem 
and progenitor cell (HSPC)-specific 
apoptosis. In contrast, lineage-specific 
deletion of  CITED2 did not result in 
such a dramatic phenotype, suggesting 
HSC-specific actions of  CITED2.
(2) These actions might be mediated 
through control of  the INK4a/ARF 
locus by the PRC1 genes BMI1 and 
MEL18.(3) In addition, TFAP2A and 
MYC have been shown to control 
cellular proliferation of  respectively 
breast and lung cancer cells using 
CITED2 as a cofactor. (4,5) The fact that 
CITED2 expression is essential for HSC 
maintenance and functions as a cofactor 
in oncogeneinduced transformation 
suggests that CITED2 could also play 
a role in leukemia initiation or leukemic 
stem cell maintenance. Gene expression 
data from Andersson et al(6) suggest that 
acute myeloid leukemic (AML) cells can 
have an enhanced CITED2 expression, 
while in chronic myeloid leukemia 
(CML), CITED2 expression is even 
further increased upon transition into 
blast crisis.(7,8) How CITED2 expression 
may be increased during leukemogenesis 
is unknown, but important transcription 
factors, like HIF1α,(9) FOXO3A(10) and 
STAT5,(5) have been shown to regulate 
its expression. Closer examination of  
the CITED2 promoter revealed that, 
besides HIF1α, FOXO3A and STAT5, 
ETS transcription factor binding sites 
are also present.
 The presence of  ETS-binding 
sites is of  interest, since a member of  
the ETS family of  transcription factors, 
PU.1, is frequently inactivated in AML. 
Although point mutations of  PU.1 are 
rarely observed,(11,12) many leukemic 
oncogenes are known to reduce or 
inactivate PU.1 expression.(11,13-17) Such 
decreased expression of  PU.1 has been 
shown to induce AML in mice.(18-20) 
Furthermore, PU.1 haploinsufficiency 
cooperates with SOX4 to induce AML 
in mice.(21) Based on these findings we 
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questioned whether PU.1 modulates 
CITED2 expression and function. 
 Here we report that a subset 
of  CD34+ AML cells express increased 
levels of  CITED2. As in normal CD34+ 
cells, this likely affects quiescence 
as well as apoptosis of  these cells. 
We furthermore demonstrate that 
reduced expression or activity of  PU.1 
contributes to this high expression of  
CITED2.
Methods
Culture conditions. Long-term 
cultures on stroma, CFC, LTC-IC 
and single cell assays were performed 
as described previously and in the 
supplementary methods.(22,23)
 Flow cytometry analysis. 
All fluorescence activated cell sorter 
(FACS) analyses were performed on a 
LSRII (Becton Dickinson (BD), Alphen a/d 
Rijn, The Netherlands) or MACSQuant 
(Myltenyi Biotec) and data was analyzed 
using FlowJo (Treestar, USA). Cells were 
sorted on a MoFLo XDP or Astrios 
(DakoCytomation, Carpinteria, CA, USA). 
Antibodies were obtained from BD 
Bioscience (Breda), Biolegend (Uithoorn), 
eBioscience (Vienna), Milteny (Leiden), 
Nuclilab (Huissen) or DAKO (Enschede) 
and are described in the supplemental 
methods.
 In vivo transplantations into 
NSG mice. Eight to ten week-old 
female NSG mice (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) were purchased 
from Charles River Laboratory and 
bred in house. Mouse experiments 
were performed in accordance with 
national and institutional guidelines 
and all experiments were approved 
by the Institutional Animal Care and 
Use Committee of  the University of  
Groningen (IACUC-RuG). Experiments 
are described in the supplemental methods.
 (Quantitative) PCR and gene 
expression profiling. RNA isolation is 
described in the supplementary methods. 
Target gene expression was investigated 
by means of  Q-PCR. Typical examples 
are shown and presented as mean with 
standard error, sequences can be found 
in supplementary table 3. A detailed 
description of  the gene expression 
analysis workflow is described in the 
supplementary methods.
 Reporter assays. For cloning 
and transfection of  constructs see 
supplemental methods.(24,25) Cells were 
harvested and lysed using Promega 
Luciferase Cell Culture Lysis 
Reagent according the manufacturers 
recommendations. Luciferase signals 
were measured using a Synergy H4 
Hybrid Reader (BioTek, Germany). 
Alternatively, the mean fluorescent in-
tensity of  GFP was measured by FACS.
 Chromatin immunoprecipita-
tions. 2.5 x 106 CD34+ cells or HL-
60 cells were used for chromatin 
immunoprecipitation studies as 
described before.(26)
Results
CITED2 enhances human HSPC 
cultures and engraftment 
Gene expression profiling suggested 
that CITED2 expression might be 
enhanced in AML cells. To study whether 
high CITED2 expression affects 
hematopoietic stem and progenitor 
cell activity, CB CD34+ cells were 
lentivirally transduced with CITED2 
(Supplementary figures 1A and B) and 
hematopoietic development was studied. 
Improved long-term expansion of  
hematopoietic cells on MS5 co-cultures 
was observed upon overexpression of  
CITED2 (Figure 1A, p<0.05), with a 
marked increase in the size (Figure 1B) 
and number (data not shown) of  week 5 
cobblestone area forming cells (CAFCs). 
To investigate the effect of  ectopic 
CITED2 expression on progenitor 
cells, transduced CD34+ cells were 
plated in methylcellulose either directly, 




culture on MS5 stromal cells. CITED2 
overexpression increased the number 
of  colony-forming-cells (CFCs) ~4-fold 
directly after transduction (Figure 1C). 
CITED2 increased CFC numbers from 
both the CD34+CD38+ and CD34+CD38- 
compartments, but subsequent 
replating capacity was confined to 
the CD34+CD38- compartment (data 
not shown). This increased progenitor 
persisted for at least 5 weeks of  culture 
(Figure 1D). These CITED2 expressing 
colonies were ~5x larger than control 
colonies (Figure 1E, note magnification), 
in line with the observed increase in 
suspension cell numbers. These colonies 
depicted a clear increase in colony-
forming-unitgranulocyte (CFU-G) 
upon overexpression of  CITED2, which 
was paralleled by a decrease in burst-
forming-unit-erythrocytes (BFU-E) 
(Supplementary figure 1C). Similar, in 
MS5-cocultures an increase in the 
percentage of  CD15+ granulocytic cells 
was observed (Supplementary figure 1D, 
upper panel), in contrast to a decrease 
in CD14+ monocytes/macrophages and 
GPA+ erythroid cells (Supplementary 
figure 1D, upper and lower panels).
 To assess whether CITED2 
overexpression also affected in 
vivo engraftment of  human cells, 
1-2x105 transduced CD34+ cells were 
transplanted into NSG mice (n=6/7) 
and at the indicated timepoints 
contribution of  human CD45+ cells to 
the peripheral blood was measured. 
Figure 1F and G demonstrate that 
CD34+ cells overexpressing CITED2 
contributed significantly better to 
human engraftment than control cells 
in 4 out of  7 transplanted mice (p<0.05). 
The higher engraftment in 4 mice 
suggested that CITED2 either affected 
migration/homing towards the BM 
or better maintained primitive HSCs. 
CXCR4 expression on both mRNA 
and protein level was not affected by 
CITED2 (Supplementary Figures 1E 
and F) and also the migration towards 
SDF-1 was not affected (Supplementary 
Figure 1G). However, within the 
bone marrow of  the high engrafting 
mice, very primitive lin-CD34+CD38-
CD90+CD45RA- cells could be detected 
at 28 weeks after transplantation, with 
a similar distribution of  HSCs, MPPs 
and LMPPs as previously published(27) 
(Supplementary Figure 1H). These 
CITED2-maintained HSCs contributed 
normally to lineage differentiation, as 
CD33 myeloid, CD19 B-cells and CD3 
T-cells were observed 24-27 weeks 
after transplantation (Figure 1H and 
Supplementary figure 1I).
Enhanced CITED2 expression 
increases quiescence of  human HSCs
As CITED2 significantly improved the 
long-term in vitro and in vivo output, it 
suggested that CITED2 has a profound 
impact on more immature human HSCs. 
LTC-IC assays with the total CD34+ 
compartment confirmed that CITED2 
overexpression increases the LTC-IC 
frequency (Supplementary figure 2A). This 
coincided with a threefold increase in the 
percentage of  immature CD34+CD38- 
HSCs after 3 days of  culture (Figures 2A 
and B). To gain further insight into how 
CITED2 increases the number of  human 
HSCs, we analyzed whether these cells 
have a changed apoptotic or cell cycle 
profile. Figure 2C demonstrates that 
Figure 1. CITED2 enhances human HSPC cultures and engraftment
A) Expansion on MS5 stromal co-culture of CB CD34+ cells lentivirally transduced with CITED2 or control lentivirus. (n=4). 
Each week cultures were demi-populated, fresh media was added and cells were counted. The average of 4 independent 
experiments is shown. Error bars denote standard deviation. * p < 0.05. B) Image of typical cobblestone forming areas (at 
10x magnification) after 5 weeks of culture on MS5 stromal cells. C) Colony forming cell numbers from CD34+ cells directly 
after transduction with lentiviral CITED2 (n=8, error bars denote standard deviation * p < 0.05). D) Colony forming cell 
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numbers after the indicated weeks on MS5 stromal cells. Each week suspension cells were harvested and interrogated for 
CFC activity (n=3, error bars denote standard deviation). Relative CFC numbers are depicted for comparison, with average 
CFC numbers per 10.000 cells plated given underneath the figure. * p < 0.05. E) Typical images of control and CITED2-
overexpressing colonies. Note that the control colonies have been taken at a 20x magnification, whereas the CITED2 
transduced colonies have been taken at a 4x magnification. F) Typical FACS plots showing human engraftment in NSG mice 
24 weeks post transplant with control or CITED2 transduced CD34+ cells. G) Human engraftment in NSG mice transplanted 
with control (n=6) or CITED2 (n=7) transduced CD34+ cells. * p < 0.05. H) Typical FACS plots showing multilineage CD3 
(T-cell), CD19 (B-cell) and CD33 (myeloid cell) engraftment at 24 weeks post transplant in a CITED2-engrafted mouse.




CITED2 decreases the percentage of  
CD34+CD38- cells that are AnnexinV+. 
As murine HSCs cycle faster upon 
CITED2 deletion,(28) we assumed that 
overexpression of  CITED2 might 
also affect human HSCs quiescence 
or proliferation. To confirm this, we 
performed Hoechst 33342/ PyroninY 
stainings to measure G0, G1 and G2/
S/M phases of  the cell cycle. As shown 
in Figure 2D, an increased fraction of  
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Figure 2. Enhanced CITED2 expression increases quiescence of human hematopoietic stem cells 
A) CD34+ CB cells were lentivirally infected with control or CITED2 and cultured in HPGM with 100 ng/ml of SCF, TPO 
and FLT3. After 2-3 days cultures were analyzed for expression of CD34 and CD38. A typical FACS analysis of HSC 
(CD34+CD38-) or progenitor cells (CD34+CD38+ ) after transduction is shown (n=15). Cells were first gated through CD271 
(tNGFR, transduced cells) and dapi (viability). B) Average percentages of CD34+CD38- HSCs of 15 CBs. Error bars denote 
standard deviation. C) CB cells were transduced, cultured and stained for CD34, CD38, CD271 and AnnexinV. The average 
of 5 CBs is shown, with error bars denoting standard deviation. D) Cell cycle FACS analysis of transduced CD34+CD38- cells. 
A representative example is shown. In the right scatter plot, the average and standard deviation of 3 samples is shown. E) 
Q-PCR analysis for CDKN1A, CDKN1B and CDKN1C after overexpression of CITED2 in CD34+CD38- HSCs. F) CB CD34+ 
cells were lentivirally infected with control, CITED2 and a lentiviral short hairpin against CDKN1A. 120 single CD34+CD38- 
HSCs were subsequently sorted into terasaki plates in IMDM plus 20% FCS and 10 ng/ml IL-3 and SCF. For 4 days of culture, 
each well was microscopically analyzed for cells that had divided or cells that had not divided (n=3). Individual experiments 
were normalized to compare. Error bars depict standard deviation.
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Figure 3. CITED2 expression is repressed by PU.1
A) Schematic representation of the human genomic CITED2 locus. Black bars indicate the two exons. The arrow in exon 2 
indicates the start of the CITED2 CDS. Black dots indicate the positions of the 5 putative ETS binding sites (GAGGAA), with 
arrows indicating Chromatin Immuno Precipitation (ChIP) primers. B=BamHI, E=EcoRI, H=HinDIII, Hi=HincII, and N=NotI 
are indicated for reference. The bottom numbers indicate numbers of nucleotides away from the start ATG. B) Chromatin 
Immuno Precipitation (ChIP) for PU.1 on CB CD34+ cells. 2-5 million CD34+ cells were crosslinked for 15 min and ChIP 
was performed with anti-PU.1 ab (Santa Cruz, sc-352) or control pre-immune serum (IgG control). Recovered genomic DNA 
was subjected to Q-PCR with the indicated primers specific for the five putative ETS binding sites. A region 10 kb upstream 
was taken along as negative control. Data is presented as relative enrichment over IgG control, and is the average of 4 
independent experiments, error bars denoting standard deviation. C) HL-60 cells were transduced with a lentivirus carrying a 
shRNAmir targeting human SPI1. Western blot analysis indicates proper knockdown (upper panel). mRNA was isolated and 
Q-PCR against CSF3R and CITED2 was performed (lower panel). D) HL-60 cells were transduced with lentiviral PU.1-ERt2 
construct. After 4-OHT (100 nM) treatment for 4 days, nuclear lysates were isolated and analyzed by western blot (upper 
panel). Bottom panel: mRNA was isolated and Q-PCR was performed for CSF3R mRNA (to indicate proper PU.1 activation) 
and CITED2 mRNA. E) Primary CB-derived CD34+ cells were transduced with SPI1 shRNAmir and subjected to mRNA 
isolation and Q-PCR analysis for SPI1 and CITED2.
HSCs remained in the G0 phase of  the 
cell cycle. Q-PCR analysis demonstrated 
that increased CITED2 expression led 
to an increased expression of  the cyclin-
dependent kinase inhibitors CDKN1B, 




CD34+CD38- compartment (Figure 2E), 
which is consistent with the enhanced 
quiescence of  these cells. To asses 
directly the involvement of  CDKN1A 
in the CITED2-mediated quiescence of  
HSCs, and to verify this observation in 
an independent assay, CD34+ cells were 
doubly transduced with a lentivirus 
expressing CITED2 and a lentivirus-
expressing a short hairpin against 
CDKN1A (Supplementary figures 2B 
and C). Subsequently, CD34+CD38- 
HSCs were single cell sorted and their 
proliferation was microscopically 
evaluated. For 4 days, each well was 
inspected for the presence of  one cell 
(quiescence) or more than one cell 
(proliferation). CITED2 expression 
indeed induced more cells to remain 
quiescent (Figure 2F). Furthermore, 
this experiment demonstrated that the 
CITED2-induced quiescence is partially 
reversible on knockdown of  CDKN1A. 
This indicates that CITED2 can 
modulate the quiescence of  HSCs by 
regulating the expression of  CDKN1A 
and thereby maintain HSCs. Although 
this CITED2-induced HSC quiescence 
is consistent with the enhanced long-
term engraftment in vivo, it seems 
contradictory to the observed expansion 
in our in vitro assays. However, 
performing the single-cell quiescence/ 
proliferation assay also on CITED2-
transduced CD34+CD38+ progenitor 
cells demonstrated that CD34+CD38+ 
progenitors are actually induced to 
proliferate (Supplementary figure 2D) 
upon transduction with CITED2, 
demonstrating differential effects of  
CITED2 on the HSC and progenitor 
compartments.
CITED2 is a direct repressive target 
of  PU.1
Next, we investigated the mechanisms 
underlying the enhanced CITED2 
expression. Besides the well studied 
HIF1α,(24) FOXO3A(9) and STAT5(10) 
binding sites, the human CITED2 
promoter containes five potential PU.1-
binding sites (Figure 3A), suggesting 
that PU.1 has a role in regulating 
CITED2 expression. ENCODE(29) 
ChIP-seq data for PU.1 in hematopoietic 
cell lines confirmed this hypothesis 
(Supplementary figure 3A). In addition, 
we first assessed PU.1 binding to the 
CITED2 promoter under relevant 
conditions, by performing chromatin 
immunoprecipitations (ChIPs) for 
endogenous PU.1 in CB-derived 
CD34+ cells. This demonstrated 
that endogenous PU.1 indeed binds 
to the CITED2 promoter (Figure 
3B). PU.1 binding to the CITED2 
promoter was independently verfied 
in PU.1-overexpressing 293T lysates 
with streptavidin pulldown assays. 
Biotinylated oligos containing the 
PU.1-binding sites from the CITED2 
promoter bound PU.1 as efficiently 
as a bona fide PU.1-binding site from 
the JUNB promoter (Supplementary 
figure 3C). Subsequently, SPI1 (the 
gene encoding human PU.1) was 
downregulated by means of  a short 
hairpin Mir-based lentivirus (Figure 
3C and Supplementary figure 3D). This 
resulted in an increase in CITED2 
expression in both HL-60 and CB CD34+ 
cells (Figures 3C and E). In contrast, 
overexpression of  a 4-hydrotamoxifen 
(4-OHT)-inducible PU.1 (PU.1-ERt2; 
Figure 3D and Supplementary figure 3E) 
in HL-60 cells led to ~2-fold decrease in 
CITED2 expression (Figure 3D).
 To study the molecular 
interaction between PU.1 and CITED2 
in more detail, the human kidney cell line 
293T was used. This cell line expresses 
high levels of  CITED2 and no PU.1. 
293T cells were transduced with PU.1-
ERt2 and activation of  PU.1 resulted in
expression of  its target genes NCF4 
(Supplementary figure 3B) and in a twofold 
reduction in CITED2 expression, 
validating this model for further studies. 
To prove that CITED2 is indeed a 
direct target of  PU.1, the CITED2 
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promoter was subcloned upstream of  a 
luciferase and/or GFP construct. After 
mutating the strongest ChIP-binding 
sites (sites 3 and 5), reporter activity 
was assessed (Supplementary figure 3F). 
A




































































































































































































Figure 4. PU.1 represses CITED2 expression through DNMT3A and B 
A) CB CD34+ cells were transduced with PU.1-ERt2 or control vector and stimulated with 100 nM 4-OH tamoxifen up to 
96 hrs, with or without 0.5 M Decitabine (DAC). Q-PCR analysis was performed to investigate CITED2 mRNA expression. 
B) 293T cells infected with PU.1-ERt2 or control vector were transduced with pGIPZ SFFV shRNAmir Scrambled (SCR), 
DNMT3A or DNMT3B and stimulated with 100 nM 4-OH tamoxifen up to 96 hrs. Data is normalized to controls. QPCR 
analysis was performed to investigate CITED2 mRNA expression (n=3). C) 293T cells infected with PU.1-ERt2 or control 
vector were transduced with a FLAG-tagged DNMT3A construct and stimulated with 100 nM 4-OH tamoxifen up to 96 
hrs. ChIP for DNMT3A ChIP was performed with anti-FLAG (M2), an antibody that specifically recognizes methylated DNA 
(MeDIP) or control pre-immune serum (IgG control). Recovered genomic DNA was subjected to Q-PCR with the indicated 
primers specific for the 3 PU.1 binding sites that showed the strongest PU.1 binding. D) The OCI-AML3 cell-line, harboring a 
DNMT3AR882C mutation, was transduced with lentiviral PU.1-ERt2, and stimulated with 100 nM 4-OHT for 4 days. mRNA 
was isolated to investigate CITED2 expression (n=3). 
Supplementary Figure 3G shows that 
activation of  PU.1 reduces activity of  the 
wild-type CITED2 (pCT2-wt) reporter. 
This reporter thus responds in the same 




promoter, validating it for further 
experiments. Mutation of  binding site 3 
showed a moderate effect (Supplementary 
figures 3H and I), but mutation of  site 
5 (pCT2-Δ5 and pCT2-Δ3Δ5) rescued 
the repression of  CITED2 by PU.1 to 
a large extent (Supplementary figures 
3H and I). Taken together, these data 
demonstrate that CITED2 is a direct 
target of  PU.1 and that activation of  
PU.1 leads to repression of  CITED2.
PU.1 represses CITED2 expression 
through DNMT3A and DNMT3B
As PU.1 has been shown to mediate 
target gene repression via DNA 
methylation,(30) we investigated whether 
methylation was also involved in 
repression of  CITED2. Therefore, 
CB CD34+ cells were transduced with 
PU.1-ERt2 and treated for 4 days with 
100 nM 4-OHT in the presence or 
absence of  0.5 μM decitabine, a DNA 
methyltransferase inhibitor. Decitabine 
completely abrogated PU.1-mediated 
repression of  CITED2 (Figure 4A), 
suggesting that PU.1 recruits DNA 
methyltransferases (DNMTs) to repress 
CITED2 expression. As CITED2 
expression is highest in immature 
cells and gradually decreases during 
myelopoiesis,(2) the de novo methylases 
DNMT3A or DNMT3B are potentially 
involved. To this end, PU.1-ERt2-
expressing 293Ts were transduced 
with lentiviruses encoding short 
hairpins targeting either DNMT3A 
or DNMT3B (Supplementary figures 
4A–C). The scrambled control-infected 
cells showed repression of  CITED2 
expression upon activation of  PU.1 
(Figure 4B, control groups). In contrast, 
suppressing DNMT3A or DNMT3B by 
means of  RNA interference rescued the 
repression of  the CITED2 promoter 
by PU.1 either partially (DNMT3A) or 
almost completely (DNMT3B) (Figure 
4B). 
 Both DNMT3A and DNMT3B 
function synergistically in the same 
complex,(31) but DNMT3A is the most 
frequently mutated DNMT3 gene in 
AML.(32) As deletion of  Dnmt3a in 
mice also resulted in expansion of  
HSC numbers,(33) we further focused 
on DNMT3A. Next, we cotransduced 
PU.1-ERt2-expressing 293Ts with 
lentiviruses encoding a FLAG-tagged 
DNMT3A construct and treated for 4 
days with 100 nM 4-OHT. A subsequent 
ChIP against FLAG demonstrated 
that activation of  PU.1 led indeed 
to recruitment of  DNMT3A to the 
CITED2 promoter at the sites that 
showed the strongest PU.1 binding 
(Figure 4C, top panels). This PU.1-
mediated recruitment of  DNMT3A 
coincided with a small increase in DNA 
methylation as measured through 
ChIP for methylated DNA (Figure 4C, 
bottom panels). Based on these data 
we hypothesized that in cells bearing 
mutations in DNMT3A, PU.1 should 
no longer be able to repress CITED2 
expression (or to a lesser extent). To 
test this, the OCI-AML3 cell line with a 
DNMT3AR882C mutation was transduced 
with PU.1-ERt2 and stimulated with 
4-OHT for 4 days. Indeed, PU.1 did 
not repress CITED2 expression in this 
cell line (Figure 4D), although PU.1 was 
activated as measured through CSF3R 
expression. Taken together, these data 
show that DNMT3A and DNMT3B 
have nonredundant functions in the 
PU.1-mediated repression of  CITED2.
CITED2 and SPI1 expression are 
inversely correlated in leukemic 
CD34+ cells
Myeloid transcription factors such 
as C/EBPα and PU.1 are frequently 
inactivated in AML.(12,23) Having 
established that PU.1 represses CITED2 
expression, we investigated whether 
CITED2 expression was enhanced in 
AML. CITED2 mRNA expression was 
analyzed by Q-PCR in AML CD34+ cells 
(n=28) and compared with CITED2 
expression in CD34+ cells from normal 
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Figure 5. CITED2 expression is necessary for leukemic stem cell maintenance
A) CD34+ cells from acute myeloid leukemia (AML, n=28) and CD34+ cells from normal bone marrow (NBM, n=9) were 
isolated and investigated for CITED2 mRNA expression by Q-PCR. B) Scatter plot analysis of CITED2 expression within 
CD34+ cells from AMLs with varying degrees of SPI1 expression. The spearman’s ranked correlation coefficient is indicated. 
C) CD34+ cells from AML no. 1 and 29 were transduced with lentiviral PU.1-ERt2 or control, 4-OHT treated for 3 days 
and mRNA was isolated. Subsequently Q-PCR was performed for CITED2. D) Representative example of AML CD34+ 
cells transduced with control hairpins (scrambled control) or short hairpins against CITED2, indicating similar transduction 
efficiencies. E) Sorting lentivirally transduced CD34+ cells from AML patients (n=7) demonstrates a ~55% knockdown 
of CITED2 mRNA expression, as measured by Q-PCR. Mean of the AMLs is presented with error bars denoting standard 
deviation. F) Lentiviral knockdown of CITED2 in CD34+ AML cells demonstrate that CITED2 expression in these cells is 
essential for inititation of long-term leukemic cultures on MS5 stromal layers. Five representative growth curves are shown. 
G) One representative AML from the nonresponsive group with low CITED2 expression demonstrates that CITED2 is not 
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bone marrow (n=9). Figure 5A shows a 
wide range of  CITED2 expression in 
AML CD34+ cells, as compared with 
normal bone marrow CD34+. Thirteen 
out of  28 AML patients displayed 
higher than normal expression. Similar 
results were obtained when compared 
with CD34+ cells from CB (n=4, data 
not shown) or granulocyte-colony 
stimulating factor-mobilized peripheral 
blood stem cells (n=5, data not shown). 
No apparent correlation between 
CITED2 mRNA expresssion and 
patient characteristics could be observed 
in our data set (Table 1). To verify these 
results, we analyzed two independent 
data sets. First, the difference in 
CITED2 expression between normal 
human bone marrow subsets and 
CD34+ selected AML samples with 
defined translocations (n=142) was 
investigated using the HemaExplorer 
website (http://servers.binf.ku.dk/hema-
explorer/).(34) Supplementary Figure 5A 
demonstrates that CITED2 expression 
was significantly higher in most AML 
samples as compared with nomal 
cellular bone marrow subsets. Second, 
also in CD34+ cells from pediatric 
AML samples (n=17, profiled by 
Andersson et al.(6)) CITED2 expression 
was found to be significantly higher 
as compared with CD34+ normal bone 
marrow cells (Supplementary Figure 
5B). Taken together, these data indicate 
that CD34+ cells from AML patients 
have higher CITED2 expression than 
normal CD34+ cells. Next, we examined 
whether a negative correlation exists 
between PU.1 and CITED2 expression. 
We therefore plotted SPI1 expression 
against CITED2 expression and we 
observed a significant inverse correlation 
between SPI1 and CITED2 expression 
(Figure 5B and Supplementary Figure 5C). 
To exclude differentiation-dependent 
effects, we phenotyped a panel of  these 
AML samples for a lymphoid-primed 
multipotent progenitor- or granulocyte–
macrophage progenitor-like phenotype.
(35) CD45RA was strongly expressed in 
all AMLs analyzed, in both CD38- and 
CD38+ compartments, suggesting that 
all AMLs displayed a granulocyte–
macrophage progenitorlike mature 
phenotype (Supplementary Figure 5D). 
As CITED2 expression is low in normal 
granulocyte–macrophage progenitors 
(Supplementary Figure 5A and data not 
shown), this supported our finding that 
CITED2 expression is aberrantly high 
in these AMLs. Subsequent bisulfate 
conversion and pyrosequencing of  12 
AML samples demonstrated a general 
hypomethylation of  the CITED2 
promoter around the PU.1-binding sites 
(Supplementary Figure 5E), consistent 
with the higher expression of  CITED2.
 Next, we investigated whether 
PU.1 also regulates CITED2 expression 
in patient AML cells. AML CD34+ cells 
were transduced with PU.1-ERt2. AML 
numbers 1 and 29 responded with a 
decreased expression of  CITED2 upon 
4-OHT treatment (Figure 5C and Table 
1). In contrast, 4 of  the 29 AML patient 
samples (AML numbers 7, 10, 11 and 21) 
contained a DNMT3AR882C/H mutation 
(Table 1), and did not show a decrease 
in CITED2 expression upon PU.1-ERt2 
activation (Table 1), similar to the results 
in the OCI-AML3 cell line (Figure 5D). 
This supports our data that DNMT3A 
is critical for PU.1 to repress CITED2, 
and together these data indicate that loss 
of  PU.1 or DNMT3A is a contributing 
factor in elevating CITED2 levels.
CITED2 is required for maintenance 
of  leukemic cultures
Gene set enrichment analysis on gene 
expression profiles of  CD34+CD38- 
HSCs after CITED2 upregulation 
indicated that various leukemia-
related signatures are enriched 
upon overexpression of  CITED2 
(Supplementary Table 1), suggesting that 
CITED2 expression has a functional 
role in AML maintenance. We 




of  leukemic origin. Taken together, 
these data demonstrate that CITED2 
is highly expressed in a subset of  AML 
CD34+ cells, and that CITED2 has a 
critical function in maintaining long-
term leukemic growth both in vitro and 
in vivo.
Discussion
We present data showing that enhanced 
expression of  CITED2 influences the 
function of  normal human HSPCs in 
vitro and in vivo and that interfering 
with CITED2 expression has a profound 
impact on primary human leukemic cells. 
We clearly demonstrate that CITED2 
expression enhances in vitro long-term 
culture and in vivo engraftment into 
NSG mice. Our human data are therefore 
not only consistent with observations in 
mice that CITED2 is required for proper 
murine HSCs function, but additionally 
demonstrate that overexpression of  
CITED2 alone is sufficient to maintain 
the primitive CD34+CD38- HSC pool 
by decreasing apoptosis and enhancing 
quiescence. This is in line with data 
from CITED2Δ/Δ mice, where deletion 
of  CITED2 resulted in actively cycling 
long-term HSCs with an increased 
apoptotic profile.(2,28) Our data indicate 
that in human HSCs CITED2 induces 
the expression of  CDKN1A and 
CDKN1C. This is slightly different from 
the experiments performed by Du et 
al.,(28) as they have shown that CITED2 
controls the expression of  the cyclin-
dependent kinase inhibitor Cdkn1c, 
but not of  Cdkn1a.(28) The mechanism 
behind this is at present unclear. 
CITED2 probably does not bind to DNA 
itself, but most likely uses CBP/p300 in 
response to various external signals.
(1,5) We functionally validated these data 
demonstrating that downregulation 
of  CDKN1A can rescue the CITED2-
induced quiescence in CD34+CD38- 
HSCs. Deletion of  Cdkn1a or Cdkn1c 
in mice resulted in a loss of  engrafting 
CITED2 in CD34+ AML cells (n = 14). 
AML CD34+ cells, transduced with 
lentiviral RNA interference vectors 
targeting CITED2 or a scrambled 
hairpin (control) (Figures 5D and E), 
were cultured on MS5 stromal cells, as 
described previously,(36) and observed for 
several weeks. Two different hairpins 
were used to knockdown CITED2, to 
minimize off  target effects, both with 
similar efficiencies and cell biologic 
results. (Supplementary Figures 6A and 
D, Supplementary Table 2). Control cells 
from AML numbers 6, 10 and 20 failed 
to expand on MS5 stromal cultures and 
were not analyzed further. Eighty-two 
percent of  the AMLs (9/11) showed 
a severely impaired expansion upon 
knockdown of  CITED2 (Figure 5F and 
Table 1). This most likely is the result of  
combined effects on cell cycle as well as 
on apoptosis. We have also analyzed the 
differentiation of  these AMLs in vitro, but 
did not observe any differences between 
shCITED2- and control-transduced 
cells (n = 11, data not shown). From 
several AMLs we compared the level 
of  knockdown to the relative decrease 
in leukemic expansion, but we could not 
detect a significant correlation between 
the two (Supplementary Fig. 6E). Lastly, 
we addressed whether knockdown of  
CITED2 also inhibits AML engraftment 
in vivo. We transduced CD34+ AML 
cells from AML numbers 30–32 with 
lentiviral control or CITED2 RNAi and 
transplanted 40, 25 or 18% GFP-sorted 
cells into NSG mice (N = 17). At 9 weeks 
post-transplant the peripheral blood of  
these mice was analyzed for the presence 
of  CD45+GFP+ cells. Supplementary 
Figures 6F and G demonstrate that 
the mice that received CITED2-
knockdown AML cells had a significant 
lower contribution of  GFP+ cells, as 
compared to the mice that received 
control transduced AML cells. As the 
phenotype of  the transplanted AML 
cells was CD34+CD33+ (Supplementary 
Figure 6G), these cells represent cells 
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binding sites on the CITED2 promoter 
(Figure 4C), although because of  
technical variation in ChIP efficiency 
this was not significant. A similar 
trend was observed toward an increase 
in methylation upon PU.1 activation 
(Figure 4C), as could be expected from 
a de novo methyltransferase. Bisulfate 
conversion and pyrosequencing in 12 
of  our AML samples demonstrated 
a general hypomethylation of  the 
CITED2 promoter around the PU.1 
binding sites (Supplementary Figure 
5E), which was consistent with the 
overall enhanced CITED2 expression 
in AML. However, it must be noted 
that the CITED2 promoter is a large 
CpG island, which are typically 
hypomethylated.(41,42) Furthermore, we 
cannot exclude the possibility that PU.1 
and DNMT3A affect the methylation of  
a currently unknown upstream enhancer 
of  CITED2. Our observations that 
in AMLs with a DNMT3A mutation 
(discovered in ~20% of  all AML 
patients(32)) PU.1 is unable to repress 
CITED2 expression is consistent with 
such a possibility.
 Whether CITED2 only 
contributes to AML maintenance 
downstream of  PU.1 or is also involved 
in leukemia initiation is not resolved. 
Our data functionally demonstrate 
that CITED2 is essential for long-
term leukemic maintenance in vitro 
and in vivo and our GSEA results 
indicate that the CITED2-induced gene 
expression programs at least partially 
overlap with published leukemia-related 
signatures (Supplementary Table 1).(43-47) 
Although overexpression of  CITED2 
changed proliferation and apoptosis 
of  HSCs and skewed myeloerythroid 
differentiation of  progenitors, no 
leukemic transformation was observed. 
This suggests that additional alterations 
are necessary.
 Taken together, our findings 
indicate that CITED2 has a critical role 
in regulating normal versus malignant 
cells upon serial transplantation.
(37,38) Thus by inducing CDKN1A/C-
mediated quiescence, CITED2 prevents 
exhaustion and hence increases overall 
hematopoiesis, as is demonstrated by 
our enhanced long-term culture and in 
vivo engraftment data.
 It appears that PU.1, one of  the 
main transcription factors involved in 
HSC maintenance and differentiation, 
affects CITED2 expression. Lowering 
PU.1 activation in human CD34+ 
cells led to an increase in CITED2 
expression, and conversely, activating 
PU.1 led to a decrease in CITED2 
expression. Previously, we observed 
that HSCs from the PU.1-knockout mice 
also showed a fourfold increase in the 
expression of  CITED2 (data not shown) 
and maintained their long-term HSCs. 
This therefore suggested that CITED2 
contributes to the maintenance of  these 
long-term HSCs and the subsequent 
development of  AML.(18,19,39)
 In AML, such a direct inverse 
correlation between CITED2 and SPI1 
expression was observed in many, but 
not all cases (Figure 5B). This most 
likely stems from the fact that many 
oncogenes affect the activation of  PU.1 
rather than its expression,(11,13,17) as well 
as the interplay with various cytokines 
and transcription factors that activate 
CITED2 expression.(5,9,10) Nevertheless, 
the decreased expression of  CITED2 
upon PU.1 reactivation in these AMLs 
is in line with our other data.
 In addition, our data 
demonstrated that both DNMT3A and 
DNMT3B knockdown interfered with 
PU.1-mediated repression of  CITED2, 
similar to its repressive function on 
p16INK4A.(30)  Since in AML both 
DNMT3A and DNMT3B mutations 
have been observed(32,40) and both factors 
are necessary for forming repressive 
complexes,(31) our data are consistent 
with such observations. Activation of  
PU.1 led to a ~2- to ~10-fold enrichment 




this results in a perturbed myeloid 
differentiation program and is likely 
to contribute to leukemic development 
and/or maintenance.
hematopoiesis. We propose a model 
where CITED2 repression during 
myelopoiesis is among others, regulated 
by PU.1, via DNMT3A/B. Together 
with diminished activation of  PU.1, 
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Long-term cultures on stroma. Cord 
blood (CB) CD34+ cells were derived from 
neonatal cord blood from healthy full-term 
pregnancies after informed consent from 
the Obstetrics departments of  the Martini 
Hospital and University Medical Center 
in Groningen, The Netherlands. AML 
blasts from peripheral blood cells or bone 
marrow cells from untreated patients with 
AML were studied after informed consent 
and the protocol was approved by the 
medical ethical committee. CB and AML 
mononuclear cells were isolated by density 
gradient centrifugation and CD34+ cells 
were selected by MiniMACS. Lentiviral 
particles were produced as described before.
(20,21) Transduction and expansion on MS5 
stromal cells in Long Term Culture (LTC) 
medium are described in the supplemental 
methods.(20,21) LTC medium (αMEM 
supplemented with heat-inactivated 12.5% 
FCS, heat-inactivated 12.5% Horse serum 
(Sigma, Zwijndrecht, The Netherlands), 
penicillin and streptomycin, 200 mM 
Glutamine, 57.2 μM β-mercaptoethanol 
(Sigma) and 1 μM hydrocortisone (Sigma).
Single cell assays. Transduced cells were 
sorted and cultured in nunclon miniwell 
trays in IMDM + 10% FCS supplemented 
with 20ng/ml c-Kit Ligand and IL-3 at 37ºC 
and 5% CO2. They were microscopically 
analyzed every day for 4-6 days. During 
these single cells cultures, ~32% of  the cells 
die due to technical reasons, which were 
discarded from further analysis.
In vivo transplantations into NSG 
mice. Before transplantations, mice were 
sublethally irradiated (2.4 Gy). Following 
irradiation mice received 3.5g/l neomycin 
in their drinking water for 2 weeks. The 
mice were injected with 1.0-2.0x105 sorted 
CD34+ cells into the tail vein immediately 
after transduction. Human cell engraftment 
was analyzed in the peripheral blood (PB) 
by flow cytometry after 6-27 weeks of  
transplantation. For the transplantation 
of  AML cells, GFP+ and GFP- transduced 
cells were sorted. Mice transplanted with 
cells from AML 30, received 300.000 cells/
mouse, 40% GFP+ ; AML 31, received 
300.000 cells/mouse, 25% GFP+ ; AML 30, 
received 160.000 cells/mouse, 19% GFP+. 
Human cell engraftment was analyzed in 
the peripheral blood (PB) by flow cytometry 
after 6-9 weeks of  transplantation. 
Lentiviral transductions. AML blasts 
were transduced in 3 consecutive rounds 
of  8 to 12 hours with lentiviral supernatant 
supplemented with 10% FCS, 20 ng/ml 
IL-3, G-CSF and TPO, and Polybrene 
(4μg/ml; Sigma) and CB CD34+ cells in 2 
consecutive rounds of  8 to 12 hours with 
lentiviral supernatant supplemented with 
c-Kit Ligand/Flt-3 ligand/TPO (100ng/ml 
each) and Polybrene (4μg/ml). HL-60 and 
OCI-M3 cells were transduced in 1 round 
of  12 hours with lentiviral supernatant 
supplemented with 10% FCS and Polybrene 
(4μg/ml).
Vectors. A pGL3 basic vector containing 
the human CITED2 promoter (-3375/+65), 
followed by a luciferase, was obtained from 
Addgene (plasmid 21486).25 Since this did 
not contain exon 2, it was named pCt2-Δ5. 
By means of  gDNA PCR the intron and 
exon 2 were inserted to create pCt2-wt. 
Both constructs were digested with EcoRI 
and XmaJI to remove the 3rd PU.1 binding 
site, creating pCt2-Δ3 and pCt2- Δ3Δ5. The 
luciferase gene wasubsequently replaced 
by a d2GFP. Human CITED2 cDNA was 
obtained through Addgene (plasmid 21487) 
26 and cloned into the multiple cloning 
site of  pRRL-SFFV-IRES-tNGFR. A 
mouse PU.1 cDNA (kind gift of  Prof. C 
Nerlov, Weatherall Institute of  Molecular 
Medicine, Oxford, UK) was also cloned into 
the multiple cloning site of  pRRL-SFFV-
IRES-tNGFR, either alone or as fusion to 
the tamoxifen responsive ERt2. pGIPZ 
shRNAmir against human SPI1, DNMT3A 
and DNMT3B were obtained from Open 
Biosystems (Thermo Scientific, USA) and the 
CMV promoter was replaced by an SFFV 
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promoter. pLKO.1 shRNA against human 
CITED2, was also obtained from Open 
Biosystems (The shRNA cassettes were 
subcloned from the puro based vector to a 
GFP based pLKO.1 vector, kindly provided 
by Dr. J. Larsson (Lund University, Lund, 
Sweden). We used 2 different hairpins to 
minimize off-target effects (Suppl. Table 3). 
We verified whether both hairpins have 
similar effects so we could use either of  
them in the leukemic culture assays.
Streptavidin pull down assay. Cell extracts 
intended for streptavidin pull down were 
made by dissolving cells in HKMG buffer, 
containing 10mM HEPES (pH 7.9), 100mM 
KCl, 5mM MgCl2, 10% glycerol 0.5% NP-
40, and freshly added 1mM DTT, 0.2mM 
PMSF and 1 mM of  a CLAP cocktail 
(chymostatin, leupeptin, antipain, pepstatin 
A) for 10 min. on ice. Lysates were made 
by sonicating samples five times for 10s 
with 30s intervals at 10 micron amplitude. 
Lysates were then spun down at 17,800 × g 
for 10 min. at 4°C, and the supernatant was 
collected and stored at -80°C as whole cell 
extract. Extracts were cleared of  aspecific 
streptavidin binding proteins by incubating 
with 25μl equilibrated Dynabeads M-280 
Streptavidin (Invitrogen, Life Technologies) 
for 1h at 4°C while rotating. Extracts were 
then cleared of  streptavidin beads using a 
magnetic rack, after which the supernatant 
was collected and incubated overnight at 
4°C with 0.115 μg of  a double stranded 
biotin-labelled oligonucleotide containing 
either one of  five pCt2 PU.1 binding sites 
or the cJun binding site, in addition to 1 μg 
of  p(dIdC). 25μl of  equilibrated Dynabeads 
was then added and allowed to incubate and 
rotate for 1h at 4°C. Samples were spun 
down at 1.000×g for 1min. at 4°C, and 20μl 
supernatant was collected as “flow through”. 
The pelleted beads were then washed in 
HKMG buffer five times before finally 
being dissolved in 20μl HKMG buffer and 
collected as “pull down”. Pull down fractions 
were then analysed using western blot.
Antibodies for flow cytometry. Leukemic 
LMPP/GMP stain: CD38--FITC (HIT2, 
BD), CD45RA-BrilliantViolet421 (HI100, 
Biolegend), CD90-Biotin (5E10, Biolegend), 
Streptavidin APC-CY7 (Biolegend), CD34-
APC (581, BD), CD123-PECy7 (6H6, 
Biolegend), CD110-PE (BAH-1, BD). 
Lineage PEcy5: CD2 (RPA-2.10, eBioscience), 
CD3 (UCHTI, eBioscience), CD4 (RPA-T4, 
eBioscience), CD7 (124-1D1, eBioscience), 
CD8 (RPA-T8, eBioscience), CD10 (MEM78, 
Biolegend), CD19 (HIB19, eBioscience), CD20 
(2H7, eBioscience), GPA (HIR2, Biolegend). 
Sort: CD34 PEcy7 (8G12, BD), CD38 PE 
(HB7, BD)/APC (HIT2, Biolegend), CD271 
PE (C40-1457, BD)/APC (ME20.4-1.H4, 
Milteny) Myelo-erythroid staining: CD14 
APC/PE (HCD14, Biolegend), CD15 APC 
(HI98, BD)/PERCP/Pacific Blue (W6D3, 
Biolegend), GPA PE/FITC (JC159, DAKO), 
CD71 AF700 (MEM-75, Nuclilab).
Gene expression profiling. From 
6 independent cord blood batches, 
CD34+ cells were MACS isolated and 
transduced with control lentivirus, 
CITED2 overexpressing lentivirus or 
a shRNA lentivirus against CITED2. 
After 2 days transduced CD34+CD38- 
were sorted from each transduction 
group (Group 1: Control-CD34+CD38- 
; Group 2: CITED2-CD34+CD38-; 
Group 3: Control-CD34+CD38+; Group 
4: CITED2-CD34+CD38+; Group 5: 
Control shSCRCD34+CD38-; Group 6: 
shCITED2-CD34+CD38-; Group 7: Control 
shSCRCD34+CD38+; Group 8: shCITED2-
CD34+CD38+. Total RNA was isolated using 
the RNeasy mini kit from Qiagen (Venlo, The 
Netherlands) according to the manufacturer's 
recommendations. Q-PCR analysis was used 
to validate proper overexpression or knock-
down of  CITED2. 2 CB samples failed this 
validation and were discarded. RNA from 
the remaining 4 cord blood was pooled 
within each group and quality was examined 
using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Waldbronn, Germany). Group 3 
and group 4 did not pass the quality criteria 
and were also discarded. On the remaining 




DNA isolation, bisulphite conversion 
and promoter-specific DNA methylation 
analysis. Genomic DNA was isolated from 
100.000 CD34+ -selected AML cells and 
bisulphite converted using the EpiTect 
Plus DNA Bisulfite kit (Qiagen, Venlo, the 
Netherlands) following the manufacturer's 
recommendations. DNA amplifications 
were performed on bisulphite-treated DNA 
using the primers indicated in suppl. table 
3. Modified DNA wasamplified in a total 
volume of  25μL. PCR products were cloned 
into the pJet1.2 vector (Thermo Scientific), 
and 12 randomly picked clones from each 
AML patient sample was sequenced. 
Alternatively, the methylation status was 
examined by pyrosequencing using a Qiagen 
pyromark Q24 system with 20μl of  the PCR 
product. Pyrosequencing reactions were set 
up using the Pyromark Gold (Q24) Reagent 
kit (Qiagen) according to the manufacturer's 
instructions. The methylation levels at the 
target CpGs were evaluated by converting 
the resulting pyrograms to numerical values 
for peak heights and expressed as the mean 
percentage of  methylation of  all CpGs 
analysed in the CITED2 promoter sequence.
was performed on Illumina (Illumina, Inc., 
San Diego, CA, USA) BeadChip Arrays 
(Illumina HT12-V4). Typically, 0.5–1 μg 
of  mRNA was used in labeling reactions 
and hybridization with the arrays was 
performed according to the manufacturer's 
instructions. The expression was quantile 
normalized using GeneSpring GX software, 
and from the probesets that were expressed 
above background (set to 25) subsequent 
fold differences were calculated. Genes that 
are positively regulated by CITED2 fulfilled 
the following criteria: Probesets that are 
above background indicate a fold change of  
2 or more; Upon CITED2 overexpression 
show an increase in expression; or upon 
knockdown of  CITED2 show a decrease 
in expression. Genes that are negatively 
regulated by CITED2 fulfilled the 
following criteria: Probesets that are above 
background indicate a fold change of  2 
or more; Upon CITED2 overexpression 
decrease in expression, or upon knockdown 
of  CITED2 increase in expression. The 
gene expression profiles were ranked based 
on fold difference and subsequently used in 
Gene Set Enrichment Analysis. Array data 
are available at http://www.ncbi.nlm.nih.gov/
geo, with accession code: GSE47218 
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Supplementary Tables
Gene sets induced by CITED2 in CD34+CD38- HSCs NES FDR
1 ELVIDGE_HYPOXIA_BY_DMOG_UP 0,45 0
2 ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 0,5 0
3 ELVIDGE_HYPOXIA_UP 0,41 0
4 ELVIDGE_HIF1A_TARGETS_DN 0,51 0
5 MENSE_HYPOXIA_UP 0,41 0
6 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 0,37 0
7 ROZANOV_MMP14_TARGETS_UP 0,3 0
8 GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP 0,49 0
9 ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP 0,41 0
10 MANALO_HYPOXIA_UP 0,32 0
11 CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP 0,37 0
12 MCLACHLAN_DENTAL_CARIES_DN 0,28 0
13 MARSON_FOXP3_TARGETS_UP 0,41 0
14 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP 0,29 0
15 MCLACHLAN_DENTAL_CARIES_UP 0,27 0
16 SEMENZA_HIF1_TARGETS 0,52 0
17 PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_UP 0,42 0
18 MISSIAGLIA_REGULATED_BY_METHYLATION_UP 0,33 0
19 HOOI_ST7_TARGETS_DN 0,38 0,001
20 NAGASHIMA_NRG1_SIGNALING_UP 0,27 0
21 KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN 0,24 0
22 CYTOSOLIC_PART 0,56 0
23 ODONNELL_TFRC_TARGETS_UP 0,23 0
24 LINDSTEDT_DENDRITIC_CELL_MATURATION_B 0,47 0,001
25 LEONARD_HYPOXIA 0,48 0,001
26 VERHAAK_AML_WITH_NPM1_MUTATED_UP 0,28 0
27 WINTER_HYPOXIA_METAGENE 0,25 0
28 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN 0,24 0
29 HARRIS_HYPOXIA 0,36 0
30 AMIT_SERUM_RESPONSE_40_MCF10A 0,48 0,001
31 RUIZ_TNC_TARGETS_UP 0,28 0
32 ONDER_CDH1_TARGETS_1_UP 0,28 0,002
33 REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS 0,4 0,003
34 BILD_HRAS_ONCOGENIC_SIGNATURE 0,24 0
35 KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 0,5 0,002
36 ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP 0,29 0
37 GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_UP 0,37 0,003
38 LIU_VAV3_PROSTATE_CARCINOGENESIS_UP 0,38 0,003
39 AMIT_EGF_RESPONSE_60_MCF10A 0,45 0,002
40 BROWNE_INTERFERON_RESPONSIVE_GENES 0,35 0,003
41 INTERCELLULAR_JUNCTION 0,55 0,001
42 GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_DN 0,3 0
43 GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN 0,38 0,003
44 MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP 0,28 0,001
45 REACTOME_GPCR_LIGAND_BINDING 0,3 0,001
46 GOLDRATH_IMMUNE_MEMORY 0,38 0,002
47 FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 0,31 0,001
48 VECCHI_GASTRIC_CANCER_EARLY_DN 0,26 0
49 WEINMANN_ADAPTATION_TO_HYPOXIA_DN 0,51 0,003
50 KOBAYASHI_EGFR_SIGNALING_24HR_UP 0,33 0,003
Gene sets repressed by CITED2 in CD34+CD38- HSCs NES FDR
1 GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN -0,31 0
2 ELVIDGE_HIF1A_TARGETS_UP -0,42 0
3 ELVIDGE_HYPOXIA_DN -0,29 0
4 ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP -0,45 0
5 WELCSH_BRCA1_TARGETS_1_DN -0,28 0
6 ELVIDGE_HYPOXIA_BY_DMOG_DN -0,4 0
7 MANALO_HYPOXIA_DN -0,2 0
8 REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION -0,52 0
9 LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT -0,42 0,001
10 OUILLETTE_CLL_13Q14_DELETION_DN -0,4 0,001
11 RNA_HELICASE_ACTIVITY -0,49 0,001
12 FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_DN -0,52 0,003
13 EXOPEPTIDASE_ACTIVITY -0,52 0,001
14 DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN -0,21 0
15 GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN -0,22 0,001
16 FAELT_B_CLL_WITH_VH3_21_UP -0,35 0,002
17 NUCLEOLAR_PART -0,52 0,002
18 KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM -0,3 0,004
19 SIG_CHEMOTAXIS -0,38 0,004
20 SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP -0,21 0
21 REACTOME_TRNA_AMINOACYLATION -0,34 0,002
22 VALK_AML_CLUSTER_4 -0,42 0,008
23 KEGG_AMINOACYL_TRNA_BIOSYNTHESIS -0,33 0,004
24 CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS -0,21 0,002
25 GARY_CD5_TARGETS_DN -0,15 0,001
26 NUCLEOLUS -0,23 0,002
27 ACTIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY -0,31 0,007
28 MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP -0,16 0
29 PROTEIN_DIMERIZATION_ACTIVITY -0,22 0,004
30 ACTIN_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS -0,27 0,006
31 PENG_GLUTAMINE_DEPRIVATION_DN -0,24 0,005
32 ACTIN_FILAMENT_BASED_PROCESS -0,25 0,007
33 NADERI_BREAST_CANCER_PROGNOSIS_UP -0,37 0,008
34 WINNEPENNINCKX_MELANOMA_METASTASIS_UP -0,19 0,005
35 YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_11 -0,23 0,008
36 FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP -0,2 0,002
37 KRASNOSELSKAYA_ILF3_TARGETS_DN -0,39 0,008
38 NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_PORT -0,38 0,008
39 ATP_DEPENDENT_HELICASE_ACTIVITY -0,38 0,008
40 ATPASE_ACTIVITY -0,22 0,006
41 SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN -0,29 0,014
42 MITSIADES_RESPONSE_TO_APLIDIN_DN -0,16 0,002
43 RNA_DEPENDENT_ATPASE_ACTIVITY -0,45 0,009
44 BROWNE_HCMV_INFECTION_20HR_UP -0,18 0,002
45 TRNA_METABOLIC_PROCESS -0,41 0,008
46 SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUP -0,18 0,004
47 BIOCARTA_RAC1_PATHWAY -0,43 0,011
48 ST_INTEGRIN_SIGNALING_PATHWAY -0,27 0,013
49 PUJANA_BRCA2_PCC_NETWORK -0,14 0,001
50 MCBRYAN_PUBERTAL_BREAST_6_7WK_UP -0,2 0,009
Supplemental table 1: GSEA results
Leukemia related signatures
Hypoxia related signatures
Supplemental table 2: Primers and probe sequences (next page)




Biotinylated Probes Forward sequence 5’- 3’ Reverse sequence 5’- 3’















































ChIP primers Forward sequence 5’- 3’ Reverse sequence 5’- 3’
prCT2, -10 kb CCACTATGGCACCAGGTAATC GGAGGTAGGGACTACTTACAC
prCT2, PU.1 site 1 GTGACCTTTCCAGGGATTTC GAAGGGGCCACTTCCTATAA
prCT2, PU.1 site2 GTGTCATGTGCCCGTATCT CCCCTCTGTCTTTTCCTAGTC
prCT2, PU.1 site 3 CCAGCTCCTGTCCTTGAAA GACCCGGACAAATAATGCG
prCT2, PU.1 site 4 AGGGCGCATTATTTGTCCG CGGTTCACCTAGCGATCTG
prCT2, PU.1 site 5 GTCTTCGGAGCAGAAATC AAATCAGCCCTCCTCATC
shRNA-shRNAmir Mature antisense ID number
pLKO.1-GFP Control TTGGTGCTCTTCATCTTGTTG NA
pLKO.1-GFP shCITED2 1 (637) AAATCCGGCATGTAGTGGTTG TRC 0000015654
pLKO.1-GFP shCITED2 2 (520) ATGAACTGGGAGTTGTTAAAC TRC 0000015655
pGIPZ SFFV Control ACGTGACACGTTCGGAGAAG NA
pGIPZ SFFV shRNAmir SPI1 GGTAGGTCATCTTCTTGCG V3THS_372921
pGIPZ SFFV shRNAmir DNMT3A ATGCTTCTGTGTGACGCTG V2LHS_202453
pGIPZ SFFV shRNAmir DNMT3B GGTAGGTCATCTTCTTGCG V2LHS_77234
pHR TRIP Control TTGGTGCTCTTCATCTTGTTG NA
pHR TRIP shCDKN1A CTCGGTGACAAAGTCGAAG NA
Sequence primers Forward sequence 5’- 3’ Reverse sequence 5’- 3’
DNMT3A GTCCGCAGCGTCACACAGAA GTGTCGCTACCTCAGTTTGC
Pyrosequence primers Forward sequence 5’- 3’ Reverse sequence 5’- 3’
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Group Mouse % CD45 % CD33 % CD19 % CD3
Control 1 3.01 5.54 68.30 0.39
2 0.98 8.70 42.10 32.90
3 0.47 87.90 3.76 0.35
4 0.40 1.19 85.10 0.26
5 0.28 77.30 1.30 0.02
6 0.19 89.80 3.93 0.15
CITED2 1 47.10 0.36 0.30 0.00
2 17.70 25.00 14.60 0.15
3 7.64 3.62 62.80 26.30
4 4.39 n.d. n.d. n.d.
5 0.88 3.26 59.90 0.98
6 0.59 1.02 3.34 0.98























































A) Schematic representation of the lentiviral CITED2 overexpression vector. B) Representative example 
of CITED2 overexpression in CD34+ CB cells (N=8) C) Colony forming cell assay for control or CITED2 
transduced CD34+ cells. To highlight differences, CFC numbers have been normalized to control and dotted 
lines have been added to emphasize same colony types. (N=8), error bars denote standard deviation. D) Typical 
FACS plots showing myeloid (upper panels: CD15/CD14, granulocytic vs. monocytic) differentiation at week 4 of 
culture on MS5 stroma cells. The lower panels show typical FACS plots for erythroid (CD71/GPA double positive 
cells), differentiation at week 2 of culture on MS5 stroma cells. (N=4) E) Relative CXCR4 mRNA expression 
after CITED2 overexpression (N=4) F) CXCR4 protein expression as measured by FACS on CD34+CD38- 
HSCs and CD34+CD38+ progenitors (N=4), error bars denote standard deviation. G) A 24-hrs migration 
assay of CITED2-transduced HSCs or progenitors towards 100 ng/ml SDF-1 (N=3, error bars denote standard 
deviation). H) FACS plots showing in vivo HSC, MPP and LMPP populations at 28 weeks after transplantation 
of CITED2 overexpressing cells. Frequencies are depicted in the upper right corner. I) Week 24 transplantation 
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Supplemental figure 2 
A) Limiting dilution analysis of transduced CD34+cells. (N=4). The average LTC-IC frequency is indicated in 
brackets. B) Schematic representation of lentiviral H1 driven short hairpin RNA vectors. C) Representative 
example of downregulation of CDKN1A (N=3). D) CB CD34+ cells were lentivirally infected with control or 
CITED2. 120 single CD34+CD38- HSCs and CD34+CD38+ progenitors were subsequently sorted into terasaki 
plates in IMDM plus 20% FCS and 10 ng/ml IL-3 and SCF. After 4 days of culture, each well was microscopically 
analyzed for cells that had divided or cells that had not divided (N=3). Individual experiments were normalized 
to compare. Error bars depict standard deviation.
Supplemental figure 3
139




1 2 3 4 5
exon 1 dGFP/luciferase
1 2 4 5
exon 1dGFP/luciferase

























































































































Potential PU. site 1 2 3 4 5
Exon 1 Exon 2ENCODE PU.1 CHiPseq tracksets
GM12878
A
D pGIPZ SFFV 
shRNAmir 
Control 5'LTR RRE ppt SFFV EGFP IRES PURO shRNAmir WPRE 3'SIN-LTR




SPI1 5'LTR RRE ppt SFFV EGFP IRES PURO shRNAmir WPRE 3'SIN-LTR
mir 5' mir 3'
SPI1
E pRRL SFFV 



































































5'LTR RRE ppt SFFV EGFP IRES PURO shRNAmir WPRE 3'SIN-LTR





5'LTR RRE ppt SFFV EGFP IRES PURO shRNAmir WPRE 3'SIN-LTR





5'LTR RRE ppt SFFV EGFP IRES PURO shRNAmir WPRE 3'SIN-LTR





































































Supplemental figure 3 
A) ChIP-seq track data of PU.1 on the CITED2 promoter in various hematopoietic cell lines obtained from 
ENCODE. The arrows indicate the potential PU.1 binding sites. B) 293T cells were transduced with lentiviral 
PU.1-ERt2 and stimulated with 4-OHT for 4 days. mRNA was isolated and QPCR for the indicated genes 
was performed (n=3) C) Biotinylated oligos for the putative SPI1 binding sites were synthesized and used 
for streptavidinmediated pulldown of proteins in cell lysates of 293T cells transduced with PU.1. The upper 
panel shows a western blot against PU.1, indicating that PU.1 can bind to these putative PU.1 binding sites. A 
canonical PU.1 binding site from the JUNB promoter was used as a positive control. The lower panel indicates 
quantification of the western blot, with the binding to the JUNB promoter as the standard set to 1. A typical 
example is shown (n=2). D) Schematic representation of the lentiviral shMir-SPI1 knockdown vector. E) 
Schematic representation of the lentiviral PU.1-ERt2 overexpression vector. F)  Schematic representation of 
the CITED2 promoter reporter constructs used. The CITED2 promoter was linked to a GFP or luciferase to 
create a CITED2 reporter vector (pCt2-wt). Subsequently, PU.1 binding sites were deleted to create pCT2-Δ3, 
pCT2-Δ5 and pCT2-Δ3Δ5 reporters. G) Control and 293T cells stable expressing PU.1 ERt2, were transfected 
with the pCt2-wt reporter and cells were stimulated with 100 nM 4-OHT. After 4 days either lysates were 
prepared and luciferase activity was measured (Luciferase vectors) or the Mean Fluorescent Intensity (MFI) 
of GFP was measured by FACS (GFP vectors). H) 293T cells infected with PU.1-ERt2 and control vector were 
transfected with the pCT2-wt, pCT2-Δ3, pCT2-Δ5 and pCT2-Δ3Δ5 reporters and stimulated with 100 nM 
4-OH tamoxifen up to 96 hrs. I) Reporter data is normalized to controls and repression of the pCT2-wt 
reporter (indicated by the arrow in H) was set to 100%.
Supplemental figure 4   
A) Schematic representation of the 
lentiviral shMir-DNMT3A and DNMT3B 
knockdown vectors. B) mRNA expression 
analysis of DNMT3A knockdown. C) 
























































































































































Supplemental figure 5   
A) Gene expression analysis using the HemaExplorer website. Significant differences in CITED2 gene 
expression between the various AML groups and the closest related normal counterpart, GMPs, is indicated. 
B) Gene expression analysis of CITED2 between CD34+ cells from 6 normal bone marrow donors (NBM) and 
17 pediatric AMLs. C) Comparison of CITED2 and SPI1 gene expression in the gene expression arrays from 
Andersson et al. demonstrating a similar trend in negative correlation between SPI1 and CITED2. D) FACS 
analysis of AML samples for CD45RA expression within the CD34+CD38- and CD34+CD38+ populations. For 
precise antibody staining, see material and methods. (N=5). E) The methylation status of the CITED2 promoter 
was examined in CD34+ cells from 12 AML patients by pyrosequencing. The methylation levels are expressed 
as the mean percentage of methylation of all CpGs analysed at the CITED2 promoter sequence with error bars 
depicting standard deviation.!
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Supplemental figure 6   
A) Schematic representation of the lentiviral U6-driven CITED2 knockdown vectors. B) Western blot analysis 
demonstrating proper knockdown of CITED2 using 2 different hairpins in CB CD34+ cells. The numbers 
indicate the starting target nucleotide. C) CFC assay demonstrating that both hairpins against CITED2 have 
comparable effects on the colony forming potential of CB CD34+ cells. D) MS5 co-cultures with transduced 
CB CD34+ cells demonstrate that both hairpins show comparable effects on growth kinetics. E) Comparison of 
expansion of CITED2 RNAi cultures relative to its control culture, with the level of CITED2 mRNA knockdown. 
F) GFP+ engraftment in NSG mice transplanted with control (n=3/AML) or shCITED2 (n=3/AML) transduced 
AML CD34+ cells. Cells were first gated through human CD45, CD33 and CD34. * indicates p<0.05. G) Top: 
typical FACS plots showing CD33/CD34 double positive cells that contribute to human GFP+ engraftment at 9 
weeks post transplant in a control-engrafted mouse. Bottom: similar plots demonstrating the absence of GFP+ 
contribution to CD33/CD34 double positive cells after knockdown of CITED2. Cells were first gated through 
human CD45.
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